HOTH News and Press, Hoth Therapeutics Inc. From 04/20/21

Shares of Hoth Therapeutics Inc. (NASDAQ:HOTH) traded at a new 52-week low today of $1.51. This new low was reached on above average trading volume as 14.2 million shares traded hands, while the average 30-day volume is approximately 4.1 million shares. Hoth Therapeutics Inc is a develop...

Gainers: Purple Biotech (PPBT) +9%, NeuroBo Pharmaceuticals (NRBO) +7%, Obalon Therapeutics (OBLN) +7%, Dare Bioscience (DARE) +4%, Hoth Therapeutics (HOTH) +2%.Losers: Syndax Pharmaceuticals (SNDX) -28%, Zai Lab (ZLAB) -13%, KalVist...

Hoth Therapeutics (HOTH) shares surge more than 17% during premarket trading after the company announces that its novel anti-cancer therapeutic exhibited positive results in humanized mast cell neoplasm models, representative in vitro and in vivo models for aggressive...

Hoth Therapeutics Announces its mRNA Frame Shifting Therapeutic Significantly Inhibits Tumor Growth in Mast Cell-Derived Cancers Reports Preclinical Data Significantly Reduces Tumor Growth in a Humanized Mast Cell Neoplasm Model for Treatment of Aggressive, Mast Cell-Derived Can...

Hoth Therapeutics Inc. (NASDAQ:HOTH) traded today at a new 52-week low of $1.50. Approximately 14.2 million shares have changed hands today, as compared to an average 30-day volume of 4.1 million shares. There is potential upside of 27.6% for shares of Hoth Therapeutics Inc. based on a c...

NEW YORK, April 13, 2021 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. today announced that the Company presented to Congressional Offices and Agencies, including HHS, NIH, FDA and the DoD on Thursday April 8th. This follows dozens of recent one-on-one briefings with Congressional staf...

Hoth Therapeutics (HOTH) has completed the formulation for HT-001, a treatment for cancer patients suffering from cutaneous toxicities (skin, nails, scalp) due to EGFR inhibitor therapies.HT-001 is expected to start its Phase 2a trial in pending approval of the IND submission.The finalization...

Hoth Therapeutics Completes HT-001 Formulation Development for Upcoming Cancer Patient Clinical Trial PR Newswire NEW YORK , April 12, 2021 /PRNewswire/ -- Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, toget...

Hoth Therapeutics ([[HOTH]] -5.6%) announces that it has engaged a full-service contract research organization Worldwide Clinical Trials for its upcoming Phase 2a dose ranging clinical trial of HT-001 for treatment of cutaneous toxicities associated with EGFR inh...

Hoth Therapeutics Engages Worldwide Clinical Trials as Contract Research Organization for Phase 2a HT-001 Clinical Trial for Cancer Patients PR Newswire NEW YORK , April 6, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biop...